First Dengue Vaccine Candidate to Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia

88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world’s first phase III efficacy study published in The Lancet – Two thirds reduction in hospitalization observed Favorable safety profile is consistent with safety documented in previous studies July 11, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced the publication in The Lancet of the detailed results …